Digital Science, a division of Macmillan Science & Education, is donating more than 15m chemical structures from world patents into the public domain through the European Bioinformatics Institute (EMBL-EBI).
In a warning to pharma groups over ‘pay-for-delay’ deals, the EU Commission has fined drug makers Johnson & Johnson (J&J) and Novartis €16m for delaying market entry of the generic pain-killer, Fentanyl.
Methods of medical treatment of the human body by administering a therapeutic drug can be deemed as patent-eligible subject matter, the High Court of Australia has held for the first time in a 4-1 decision.
A coalition of public interest groups have filed an amici curiae brief with the US Supreme Court accusing the federal circuit of misinterpreting the Patent Act’s exceptional case statute for damages, calling to tighten up the standard around fee shifting.
Rapid growth in China drives patent market, industrial-design registration sees best-ever rate of growth.
The Goodlatte bill indiscriminately treats all plaintiffs as patent trolls and will ultimately make patent rights harder to enforce
India’s policy of issuing compulsory licences for life-saving drugs has been welcomed by its thriving generics industry, but has drawn the ire of big pharma, Remfry & Sagar’s Swarup Kumar describes some of the issues involved
The makers of Jägermeister ended up opposite the Tamil Nadu Police over a ‘don’t drink and drive’ campaign, explains Remfry & Sagar’s Gaurav Mukerjee
Sughrue Mion’s Natalya Dvorson explores situations where a provisional application filed before the America Invents Act could lose its earlier filing date.
EMAIL NEWSLETTER SIGN UP
Intellectual Property Enterprise Court - 24 October 2013
Court of Justice of the European Union - 17 October 2013
US Court of Appeals for the Federal Circuit - 22 July 2013
US District Court, US Court of Federal Claims - various dates